Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4509266 | 0.93 | SLC2A1 (0.48) | SLC2A1CA12CA1CA2CA4 | |
| SCHEMBL4516916 | 0.89 | SLC2A1 (0.46) | SLC2A1CA12CA1CA2CA4 | |
| SCHEMBL3940954 | 0.88 | SLC2A1 (0.43) | SLC22A12SLC2A1CA12CA1CA2 | |
| SCHEMBL3945671 | 0.87 | SLC2A1 (0.42) | SLC22A12SLC2A1CA12CA1CA2 | |
| SCHEMBL3936271 | 0.86 | SLC2A1 (0.42) | SLC22A12SLC2A1CA12CA1CA2 | |
| SCHEMBL4509362 | 0.86 | SLC22A12 (0.42) | SLC22A12SLC2A1CA12CA1CA2 | |
| SCHEMBL3941729 | 0.85 | CA1 (0.48) | SLC2A1CA12CA1CA2CA4 | |
| SCHEMBL4517904 | 0.84 | CA1 (0.49) | CA12CA1CA2CA4MAOB | |
| SCHEMBL3946314 | 0.84 | SLC2A1 (0.42) | SLC22A12SLC2A1CA12CA1CA2 | |
| SCHEMBL3937859 | 0.83 | CA1 (0.43) | SLC2A1CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264425-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED | 2009-10-22 | — | — | US | claimed |
| EP-1831157-A2 | NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | Pfizer Limited (GB) | 2007-09-12 | — | — | EP | claimed |
| WO-2006067587-A2 | NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | PFIZER LIMITED (GB) | 2006-06-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264425-A1 | CHEMICAL COMPOUNDS | POLR2E, POLR2A, POLRMT | SLC22A12 4402/4885SLC2A1 4452/4885CA12 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.